Paolo Tarantino: Thanks to ESMO for featuring our 5-year analysis of the ATEMPT randomized phase 3 trial
Journal of Clinical Oncology. .
Authors: Paolo Tarantino, Nabihah Tayob, Guillermo Villacampa, Chau Dang, Denise A. Yardley, Steven J. Isakoff, Vicente Valero, Meredith Faggen, Therese Mulvey, Ron Bose, Douglas Weckstein, Antonio C. Wolff, Katherine Reeder-Hayes, Hope S. Rugo, Bhuvaneswari Ramaswamy, Dan Zuckerman, Lowell Hart, Vijayakrishna K. Gadi, Michael Constantine, Kit Cheng, Audrey Merrill Garrett, P. Kelly Marcom.
Kathy Albain, Patricia DeFusco, Nadine Tung, Blair Ardman, Rita Nanda, Rachel C. Jankowitz, Mothaffar Rimawi, Vandana Abramson, Paula R. Pohlmann, Catherine Van Poznak, Andres Forero-Torres, Minetta C. Liu, Kathryn J. Ruddy, Adrienne G. Waks, Michelle DeMeo, Harold J. Burstein,Ann H. Partridge, Patrizia Dell’Orto, Leila Russo, Emma Krause, Daniel J. Newhouse, Busem Binboğa Kurt, Elizabeth A. Mittendorf, Bryan Schneider, Aleix Prat, Eric P. Winer, Ian E. Krop and Sara M. Tolaney.
“Thanks to ESMO – European Society for Medical Oncology for featuring our 5-year analysis of the ATEMPT randomized phase 3 trial, showing:
- Outstanding efficacy of adjuvant T-DM1 at preventing recurrence from stage I HER2+ breast cancer (5y RFI 98.3%).
- Favorable tolerability, with improved quality of life over chemotherapy.
- Promising role of HER2DX for risk prediction.
- Several insights on the biology and heterogeneity of HER2+ breast cancer.
Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.
His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.